A biopharma business with bases in Wetherby and Cambridge has added an industry veteran to its senior team as it transitions into a clinical stage biotech company.
Paul Fry joins Avacta Group as Non-Executive Director, bringing with him extensive financial experience across the pharmaceutical, biotech and telecoms industries.
Before the appointment takes effect on 3 February, Mr Fry will continue to serve as Chief Financial Office of listed inhaled drug delivery company, Vectura Group. He will also be appointed Chair of the Audit Committee.
Prior to his role at Vectura, he served as CFO of biotech company Immunocore. He was also Director of Global Finance Operations at Vodafone and spent over 25 years at GlaxoSmithKline.
“Paul has significant financial and commercial experience in the pharmaceutical and biotech sector and his appointment reflects our commitment to attracting the best talent to the Company,” said Dr Eliot Forster, Chairman of Avacta Group.
“We look forward to working with him as Avacta develops into a clinical stage biotechnology company.”
Mr added: “I am excited by the opportunity to work with Avacta in their mission to develop novel cancer immunotherapies and to commercialise the Affimer technology in other markets.”